Medivant Health builds generic drug production facility in Chandler


Medivant, a new pharmaceutical manufacturer has selected Chandler to build a 33,000-square-foot facility to make generic drugs on the FDA shortage list.

Medivant Health is renovating this 33,000-square-foot manufacturing plant in Chandler to make generic drugs that are on the FDA’s list of drugs in short supply.

Medivant Health is currently building a 33,000-square-foot generic drug manufacturing facility in Chandler, Arizona. The first phase will create 10,000 square feet of manufacturing and laboratory space able to produce 40,000 vials of generic drug products every day. Medivant is a new Current Good Manufacturing Practice (CGMP) Manufacturer. Medivant is unique in that its sole purpose is to fill this generic drug shortage void. The facility is fully automated with minimal human intervention.

It’s a crisis most people and patients never know about, the shortage of some of the most common generic drugs. The numbers are scary, and surprising. 

• 160+ drugs are on the FDA’s short supply list

• 98% of hospital drug shortages are injectable generic drugs that cost less than $10.

• 80% of hospitals increased spending due to drug shortages. 

“Take the simple example of lidocaine which has been used consistently by hospitals for nearly 50 years,” said Medivant Health’s Head of Quality, Andrew Stasiak, CQA. “There are huge shortages of generic medicines like lidocaine because almost none of the other drug manufacturers will make it due to the small profit margin compared to other drugs which sell for much higher prices.” 

The timing of Medivant’s launch comes at the perfect time. In January 2020, new Good Manufacturing Practice (GMP) compliance standards will be enforced, and many compounding pharmacies are likely struggle to comply with the standards and the additional expenses, potentially making shortages even worse. 

The Medivant Facility

About Medivant Facility

The Medivant facility is a full-scale CGMP Plant, not just a compounding facility. It is a fully automated manufacturing facility, creating aqueous sterile injectable products in a single line designed by a leading pharmaceutical design firm. Medivant intends to manufacture single dose liquid vials between 1 ml & 10 ml. 

Medivant plans on producing more than 20 generic molecules which will be available for purchase by hospitals, surgical centers, emergency centers, and even some doctors’ offices. Group Purchasing Organizations (GPOs) which sell products in bulk to hospitals nationwide have already begin discussions with Medivant and are expressing excitement that the company will help fill a major need in the market.